Copyright 2020 American Medical Association. All rights reserved.

Association Between Aspirin Use and Biliary Tract Cancer Survival

Biliary tract cancers (BTCs) are rare, with a worldwide incidence of less than 2 per 100,000 individuals.\(^1\) The 5-year survival rate ranges from 5% to 15%, with a median survival of less than 1 year.\(^1\) Between 60% and 70% of patients present with late-stage disease (eg, inoperable or metastatic tumors) owing to the lack of symptoms.\(^3\) Consequently, there is a critical need for treatments that improve BTC survival. Aspirin has been proposed as a treatment to reduce cancer mortality because it may slow cancer growth through the inhibition of both cyclooxygenase 2, which promotes inflammation and cell proliferation,\(^3\) and platelet aggregation, which may slow the metastatic spread of cancer.\(^4\) We investigated the association between postdiagnosis aspirin use and BTC survival.

Methods | This study was approved by the National Institutes of Health Human Research Protection Program and the Independent Scientific Advisory Committee of the Clinical Practice Research Datalink (CPRD) Protocol I7_160.R, and it was deemed exempt from patient written consent requirements because it was conducted using deidentified data. We obtained data, including all-cause deaths, on adult patients diagnosed with BTC from 1990 through 2017 from the United Kingdom’s CPRD, an electronic medical record database. We identified cancers using Read codes for gallbladder cancer (GBC), cholangiocarcinoma, ampulla of Vater cancer (AVC), and overlapping lesions of the biliary tract. We excluded patients with previous cancer, except for nonmelanoma skin cancer.

Ever use of postdiagnosis aspirin was defined as 1 prescription or more recorded in the CPRD on or after the BTC diagnosis date. We used Cox proportional hazards regression models to estimate the cancer site-specific hazard ratios (HRs) and 95% CIs for the association between time-dependent postdiagnosis aspirin use and overall survival. Patients who received an aspirin prescription within 30 days of diagnosis entered the model as users. The time scale began at diagnosis until death, exit from the study, or the end of follow-up (truncated at 10 years). We adjusted for the following covariates a priori: age at diagnosis, sex, comorbidities, statin use at diagnosis, indicators of a healthy lifestyle, and year of diagnosis. We fit separate models for each BTC type and stratified the baseline hazard by prediagnosis aspirin use (yes/no). We estimated adjusted survival curves using a marginal approach to remove the sex and age effects on aspirin use, accounting for the time-dependent exposure.\(^3\) We conducted analyses from April to May 2019 using SAS (version 9.4; SAS Institute) and survival curves in R Studio (version 1.1.453).

Results | Among the eligible 2934 patients with BTC, 667 (23%) had GBC; 1559 (53%) cholangiocarcinoma; 224 (8%) AVC; and numbers represent aspirin use at the time of BTC diagnosis.

<table>
<thead>
<tr>
<th>BTC Site</th>
<th>No. at Risk</th>
<th>HR (95% CI)</th>
<th>No. at Risk</th>
<th>HR (95% CI)</th>
<th>No. at Risk</th>
<th>HR (95% CI)</th>
<th>No. at Risk</th>
<th>HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gallbladder</td>
<td>Non-users</td>
<td>499/600</td>
<td>1 (Reference)</td>
<td>1198/1419</td>
<td>1 (Reference)</td>
<td>116/186</td>
<td>1 (Reference)</td>
<td>360/437</td>
</tr>
<tr>
<td></td>
<td>Users</td>
<td>54/67</td>
<td>0.63 (0.48–0.83)</td>
<td>123/140</td>
<td>0.71 (0.60–0.85)</td>
<td>26/38</td>
<td>0.44 (0.26–0.76)</td>
<td>39/47</td>
</tr>
<tr>
<td>Cholangiocarcinoma</td>
<td>Non-users</td>
<td>354/455</td>
<td>1 (Reference)</td>
<td>815/1036</td>
<td>1 (Reference)</td>
<td>83/153</td>
<td>1 (Reference)</td>
<td>241/318</td>
</tr>
<tr>
<td></td>
<td>Users</td>
<td>5/17</td>
<td>0.57 (0.28–1.17)</td>
<td>9/26</td>
<td>0.37 (0.21–0.64)</td>
<td>0/12</td>
<td>0.21 (0.03–1.56)</td>
<td>2/9</td>
</tr>
<tr>
<td>Ampulla of Vater</td>
<td>Non-users</td>
<td>145/145</td>
<td>1 (Reference)</td>
<td>383/383</td>
<td>1 (Reference)</td>
<td>33/33</td>
<td>1 (Reference)</td>
<td>119/119</td>
</tr>
<tr>
<td></td>
<td>Users</td>
<td>49/50</td>
<td>0.69 (0.50–0.94)</td>
<td>114/114</td>
<td>0.78 (0.65–0.95)</td>
<td>26/26</td>
<td>0.41 (0.22–0.79)</td>
<td>37/38</td>
</tr>
<tr>
<td>Overlapping Lesions</td>
<td>Non-users</td>
<td>1/12</td>
<td>0.37 (0.21–0.64)</td>
<td>3/5</td>
<td>0.37 (0.21–0.64)</td>
<td>0/1</td>
<td>0.03–1.56</td>
<td>0/1</td>
</tr>
<tr>
<td></td>
<td>Users</td>
<td>0.21</td>
<td>0.21 (0.03–1.56)</td>
<td>0.34</td>
<td>0.34 (0.12–0.94)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: BTC, biliary tract cancer; HR, hazard ratio; NA, not applicable.

\(^{a}\) Adjusted for sex, history of heart disease, statin use (current, former, never), presence of comorbidities, age at diagnosis, and year of diagnosis. Aspirin use was modeled as time dependent and the baseline hazard was stratified by prediagnosis aspirin use.

\(^{b}\) The results presented used Cox regression where aspirin was modeled as time dependent (eg, individuals could switch between use and nonuse status). The interaction \(P\) value for interaction was estimated by putting a cross-product term in the models for postdiagnosis use and prediagnosis use.

\(^{c}\) Prevalent users were defined as patients with 2 or more aspirin prescriptions before BTC diagnosis. Incident users were defined as patients who only initiated aspirin use on or after the BTC diagnosis date.

\(^{d}\) Numbers represent aspirin use at the time of BTC diagnosis.
484 (16%) overlapping. There were 2415 deaths (82%), with a median survival of 5.8 (interquartile range, 2-15) months.

Two-hundred and fifty-six (9%) patients were aspirin users at baseline, with an additional 349 (12%) patients initiating aspirin use after diagnosis. Ninety-six percent of aspirin users (n = 2817) were prescribed a 75-mg dose. Compared with nonusers, aspirin users were more likely to be older, current statin users, and prediagnosis aspirin users and were more likely to have heart disease and comorbidities.

Aspirin use was associated with decreased risk of death in patients with GBC (HR, 0.63; 95% CI, 0.48-0.83), cholangiocarcinoma (HR, 0.71; 95% CI, 0.60-0.85), AVC (HR, 0.44; 95% CI, 0.26-0.76), and overlapping BTC (HR, 0.68; 95% CI, 0.50-0.92) (Table). The survival probabilities are shown in the Figure. Incident users with no history of aspirin use had a larger benefit from postdiagnosis aspirin use than prevalent users, although all users had a reduction in risk of death.

Discussion | We observed a reduced risk of death for postdiagnosis aspirin users across all BTC types. Platelet activation protects tumor cells from elimination, enhances metastatic cell growth, and enables cancerous cells to spread via the bloodstream. Aspirin may slow the metastatic spread of cancer cells through inhibition of platelet aggregation, improving BTC survival. A limitation of our analysis is the lack of data on cancer stage and chemotherapy regimens received (if any). However, most BTCs are diagnosed at late stage with less than 10% of patients presenting with resectable tumors and 50% of tumors metastasizing to the lymph nodes. The survival benefit of aspirin observed in our study is on par with the current standard of care.
Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View

To the Editor We read with great interest the article published in JAMA Oncology by Berner and colleagues,1 which was the first study, to our knowledge, to show a potential mechanism of skin immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). Clinical studies have enhanced the understanding of irAEs in a clinical but not pathophysiological view. This study1 found that patients with non-small cell lung cancer who were treated with a programmed cell death 1 (PD-1) inhibitor and experienced skin irAEs had a higher response rate and longer overall survival than those without skin irAEs. By analyzing the T-cell receptor (TCR) clones from peripheral blood mononuclear cells, tumor biopsy specimens, and biopsy specimens from the sites of skin irAEs, Berner et al2 revealed that some shared antigens were present in both lung tumors and the skin. The study had meaningful findings, and we support most of the conclusions, but we have several concerns about the study.

First, the duration of treatment may be an important confounding factor that could affect the association between irAEs and efficacy. Longer duration of ICI treatment has been associated with a higher rate of adverse events.2 However, the treatment duration was not reported in this study. Duration of treatment and onset time of skin irAEs should be reported to better explain the conclusion.

The second concern is about the site from which the pretreatment tumor specimen was obtained for the sequencing. With a better understanding of the temporal and spatial heterogeneity of the tumor, the primary tumor or metastasis site and advanced or recurrent disease provide different genomic information.3 In lung cancer, TCR intratumor heterogeneity has been reported.4 In addition, the dynamics of changes in the complementary determining region 3 of TCR during nivolumab treatment have been described.5 However, Berner et al2 did not address the site of the tumor sample. Knowing the site of the pretreatment tumor sample (primary tumor or metastasis) and the patients’ disease stage (advanced or recurrent) would help us to better understand the mechanism of skin irAEs associated with ICI therapy.

The conclusion that lung tumors and the skin share some of the same self-antigens should be validated in larger cohort studies. If necessary, repeat tumor biopsy specimens obtained before and during treatment should be matched with specimens from the sites of skin irAEs to confirm a pathophysiological mechanism. Additional analysis of the pathophysiological mechanism will improve the understanding of irAEs, allowing clinicians to better manage them and to maximize the therapeutic efficacy of ICIs.

Xu Yang, MD
Jianzhen Lin, MD
Haitao Zhao, MD

Author Affiliations: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

COMMENT & RESPONSE

Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View

To the Editor We read with great interest the article published in JAMA Oncology by Berner and colleagues,1 which was the first study, to our knowledge, to show a potential mechanism of skin immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). Clinical studies have enhanced the understanding of irAEs in a clinical but not pathophysiological view. This study1 found that patients with non-small cell lung cancer who were treated with a programmed cell death 1 (PD-1) inhibitor and experienced skin irAEs had a higher response rate and longer overall survival than those without skin irAEs. By analyzing the T-cell receptor (TCR) clones from peripheral blood mononuclear cells, tumor biopsy specimens, and biopsy specimens from the sites of skin irAEs, Berner et al2 revealed that some shared antigens were present in both lung tumors and the skin. The study had meaningful findings, and we support most of the conclusions, but we have several concerns about the study.

First, the duration of treatment may be an important confounding factor that could affect the association between irAEs and efficacy. Longer duration of ICI treatment has been associated with a higher rate of adverse events.2 However, the treatment duration was not reported in this study. Duration of treatment and onset time of skin irAEs should be reported to better explain the conclusion.

The second concern is about the site from which the pretreatment tumor specimen was obtained for the sequencing. With a better understanding of the temporal and spatial heterogeneity of the tumor, the primary tumor or metastasis site and advanced or recurrent disease provide different genomic information.3 In lung cancer, TCR intratumor heterogeneity has been reported.4 In addition, the dynamics of changes in the complementary determining region 3 of TCR during nivolumab treatment have been described.5 However, Berner et al2 did not address the site of the tumor sample. Knowing the site of the pretreatment tumor sample (primary tumor or metastasis) and the patients’ disease stage (advanced or recurrent) would help us to better understand the mechanism of skin irAEs associated with ICI therapy.

The conclusion that lung tumors and the skin share some of the same self-antigens should be validated in larger cohort studies. If necessary, repeat tumor biopsy specimens obtained before and during treatment should be matched with specimens from the sites of skin irAEs to confirm a pathophysiological mechanism. Additional analysis of the pathophysiological mechanism will improve the understanding of irAEs, allowing clinicians to better manage them and to maximize the therapeutic efficacy of ICIs.

Xu Yang, MD
Jianzhen Lin, MD
Haitao Zhao, MD

Author Affiliations: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.

COMMENT & RESPONSE

Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View

To the Editor We read with great interest the article published in JAMA Oncology by Berner and colleagues,1 which was the first study, to our knowledge, to show a potential mechanism of skin immune-related adverse events (irAEs) induced by immune checkpoint inhibitors (ICIs). Clinical studies have enhanced the understanding of irAEs in a clinical but not pathophysiological view. This study1 found that patients with non-small cell lung cancer who were treated with a programmed cell death 1 (PD-1) inhibitor and experienced skin irAEs had a higher response rate and longer overall survival than those without skin irAEs. By analyzing the T-cell receptor (TCR) clones from peripheral blood mononuclear cells, tumor biopsy specimens, and biopsy specimens from the sites of skin irAEs, Berner et al2 revealed that some shared antigens were present in both lung tumors and the skin. The study had meaningful findings, and we support most of the conclusions, but we have several concerns about the study.

First, the duration of treatment may be an important confounding factor that could affect the association between irAEs and efficacy. Longer duration of ICI treatment has been associated with a higher rate of adverse events.2 However, the treatment duration was not reported in this study. Duration of treatment and onset time of skin irAEs should be reported to better explain the conclusion.

The second concern is about the site from which the pretreatment tumor specimen was obtained for the sequencing. With a better understanding of the temporal and spatial heterogeneity of the tumor, the primary tumor or metastasis site and advanced or recurrent disease provide different genomic information.3 In lung cancer, TCR intratumor heterogeneity has been reported.4 In addition, the dynamics of changes in the complementary determining region 3 of TCR during nivolumab treatment have been described.5 However, Berner et al2 did not address the site of the tumor sample. Knowing the site of the pretreatment tumor sample (primary tumor or metastasis) and the patients’ disease stage (advanced or recurrent) would help us to better understand the mechanism of skin irAEs associated with ICI therapy.

The conclusion that lung tumors and the skin share some of the same self-antigens should be validated in larger cohort studies. If necessary, repeat tumor biopsy specimens obtained before and during treatment should be matched with specimens from the sites of skin irAEs to confirm a pathophysiological mechanism. Additional analysis of the pathophysiological mechanism will improve the understanding of irAEs, allowing clinicians to better manage them and to maximize the therapeutic efficacy of ICIs.

Xu Yang, MD
Jianzhen Lin, MD
Haitao Zhao, MD

Author Affiliations: Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.